Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 20;17(5):77.
doi: 10.3390/neurolint17050077.

Medications for Managing Central Neuropathic Pain as a Result of Underlying Conditions-A Systematic Review

Bjarke Kaae Houlind  1 , Henrik Boye Jensen  1
Affiliations
Review

Medications for Managing Central Neuropathic Pain as a Result of Underlying Conditions-A Systematic Review

Bjarke Kaae Houlind et al. Neurol Int. .

Abstract

Background: This systematic review assessed the current literature regarding the analgesic treatment of central neuropathic pain (CNP) in central nervous system (CNS) conditions, such as spinal cord injuries, multiple sclerosis, post-stroke disorders, and Parkinson's disease. The aim of this systematic review was to compare the current algorithmic treatment of CNP, which generally does not discriminate among underlying conditions, with RCTs investigating algorithm-recommended and non-algorithm-recommended drugs for differing underlying conditions. Methods: The PubMed and EMBASE databases were used to identify relevant randomized control trials (RCTs). MeSH terms and EmTree terms were searched as well as free text words in the title/abstract of the studies. A risk of bias tool was used to assess all included studies. Results: A total of 903 RCTs were identified from the initial search. Thirty-eight RCTs published between January 2002 and November 2024 fulfilled all the inclusion criteria and none of the exclusion criteria. The review investigated progressive and stable neurological diseases and conditions with associated CNP. Conclusions: From the majority of the included studies, the current recommended treatment algorithm seems to be effective and safe; however, the underlying condition seems to influence how the patient responds to tier-appropriate medication.

Keywords: central neuropathic pain; neuralgia; neuropathic pain; systematic review.

PubMed Disclaimer

Conflict of interest statement

H.B.J. has received travel grants from Novartis and Merck and speaker honorarium from Novartis. The authors declare no other conflicts of interests.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram showing the included and excluded studies and the reasons for exclusion.
Figure 2
Figure 2
Literature search string from EMBASE and PubMed.
See this image and copyright information in PMC

References

    1. Vranken J.H., Dijkgraaf M.G., Kruis M.R., van Dasselaar N.T., van der Vegt M.H. Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: A placebo-controlled trial. Pain. 2005;118:224–231. doi: 10.1016/j.pain.2005.08.020. - DOI - PubMed
    1. Langford R.M., Mares J., Novotna A., Vachova M., Novakova I., Notcutt W., Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 2013;260:984–997. doi: 10.1007/s00415-012-6739-4. - DOI - PubMed
    1. Agarwal N., Joshi M. Effectiveness of amitriptyline and lamotrigine in traumatic spinal cord injury-induced neuropathic pain: A randomized longitudinal comparative study. Spinal Cord. 2017;55:126–130. doi: 10.1038/sc.2016.123. - DOI - PubMed
    1. Svendsen K.B., Jensen T.S., Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br. Med. J. 2004;329:253–257. doi: 10.1136/bmj.38149.566979.AE. - DOI - PMC - PubMed
    1. Mahesh B., Singh V.K., Pathak A., Kumar A., Mishra V.N., Joshi D., Chaurasia R.N. Efficacy of Duloxetine in Patients with Central Post-stroke Pain: A Randomized Double Blind Placebo Controlled Trial. Pain Med. 2023;24:610–617. doi: 10.1093/pm/pnac182. - DOI - PubMed

LinkOut - more resources